Table 1.
Patients’ demographics and characteristics.
| Total (n = 198) | ||
|---|---|---|
| Frequency (N = 198) | % | |
| Gender | ||
| Male | 125 | 63.1 |
| Female | 73 | 36.9 |
| Median Age | 66.3 years (20–88) | |
| ≤70 years | 121 | 61.1 |
| >70 years | 77 | 38.9 |
| Tumor Location | ||
| Colon/Sigmoid | 129 | 65.2 |
| Rectum | 69 | 34.8 |
| Grade | ||
| I-II | 116 | 60.4 |
| III | 76 | 39.6 |
| Unknown | 6 | |
| Surgery | ||
| Yes | 148 | 74.7 |
| No | 50 | 25.3 |
| Metastasectomy | ||
| Yes | 39 | 19.7 |
| No | 159 | 80.3 |
| Performance Status (ECOG *) | ||
| 0–1 | 179 | 90.4 |
| 2 | 19 | 9.6 |
| CEACAM5 **+/EpCAM ***+/CD45 #- | ||
| Positive | 66 | 33.3 |
| Negative | 132 | 66.7 |
| CEACAM5+/EpCAM-/CD45- | ||
| Positive | 111 | 56.1 |
| Negative | 87 | 43.9 |
| CEACAM5-/EpCAM+/CD45- | ||
| Positive | 17 | 8.6 |
| Negative | 181 | 91.4 |
| CEACAM5mRNA (cutoff >0.91 Lovo cell equivalents) | ||
| Positive | 18 | 90.9 |
| Negative | 18 | 9.1 |
| KRAS ## exon 2 mutations | ||
| Mutated | 85 | 45 |
| Wild type | 104 | 55 |
| Not Determined | 9 | |
| BRAFV600E mutations | ||
| Mutated | 15 | 7.8 |
| Wild type | 177 | 92.2 |
| Not Determined | 6 | |
| Microsatellite Instability (MSI) | ||
| MSI-High | 8 | 4.9 |
| MSI-Stable (MSS) | 155 | 95.1 |
| Not Determined | 35 | |
* ECOG: Eastern Cooperative Oncology Group; ** CEACAM5: carcino-embryonic antigen-like cellular adhesion molecule 5; *** EpCAM: epithelial cellular adhesion molecule; # CD45: cluster of differentiation 45; ## KRAS: Kirsten rat sarcoma.